Royalty Pharma

Pablo Legorreta, the founder, serves as Chief Executive Officer and Chairman, directing all material investment and capital-allocation decisions. The firm also employs a specialist team with deep pharma, scientific, and financial expertise to evaluate royalty opportunities. Legorreta has led Royalty Pharma since its founding in 1996.

Royalty Pharma sources primarily through direct relationships with academic institutions, biotech innovators, and large pharmaceutical companies seeking to monetize royalty streams. Its position as the largest and most active buyer in the market means that sellers frequently approach the firm directly. The firm does not rely on auctions or intermediaries as a primary channel.

Royalty Pharma is a publicly traded company listed on Nasdaq under the ticker RPRX. Unlike traditional private equity or venture funds, it is a permanent capital vehicle with no fixed fund life, enabling it to hold royalty assets for decades and match the underlying patent protected cash flow durations of the therapies it finances.

No. The firm exclusively acquires revenue interests in the form of royalties and milestones on approved or late-stage development products. It does not purchase common stock, take board seats, or involve itself in the operational management of the companies whose royalty streams it owns.

The firm's portfolio spans immunology, oncology, neurology, rare genetic diseases, cardiovascular conditions, and metabolic disorders. Notable assets include royalties on Vertex's cystic-fibrosis portfolio, Biogen's multiple-sclerosis and spinal muscular atrophy therapies, and Johnson & Johnson's immunology franchise.

The firm holds interests in more than 35 commercial and development-stage therapies. In 2024 it completed $2.4 billion in new royalty acquisitions (per the firm's annual report, 2024), and it reports a pipeline of additional opportunities sourced from its position as the market's dominant buyer.

While its primary focus is approved and late-stage assets, the firm has increasingly provided development-stage funding through pre-approval royalty acquisitions. Its portfolio includes royalty interests in therapies still in clinical trials, such as certain candidates from MorphoSys, Biohaven, and other platform companies, acquired before regulatory approval.